AR078498A1 - Tratamiento de calvicie de patron masculino por induccion local del defecto metabolico de la enfermedad de fabry - Google Patents

Tratamiento de calvicie de patron masculino por induccion local del defecto metabolico de la enfermedad de fabry

Info

Publication number
AR078498A1
AR078498A1 ARP100103588A ARP100103588A AR078498A1 AR 078498 A1 AR078498 A1 AR 078498A1 AR P100103588 A ARP100103588 A AR P100103588A AR P100103588 A ARP100103588 A AR P100103588A AR 078498 A1 AR078498 A1 AR 078498A1
Authority
AR
Argentina
Prior art keywords
phase
inhibitors
galactosidase
derivatives
alpha
Prior art date
Application number
ARP100103588A
Other languages
English (en)
Inventor
Raphael Schiffmann
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of AR078498A1 publication Critical patent/AR078498A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente describe el uso de un inhibidor de la enzima lisosomal alfa-galactosidasa A para favorecer el crecimiento del cabello o para prevenir la caída del cabello. El uso topico de la composicion de la presente solicitud inhibe en forma directa la actividad enzimática en el cuero cabelludo y se usa en el tratamiento de la calvicie de patron masculino (alopecia androgénica) en hombres y mujeres. Reivindicacion 1: Una formulacion farmacéutica topica para estimular el crecimiento del cabello, prevenir la caída del cabello, o tratar la calvicie y la alopecia en un humano, caracterizada porque comprende: uno o más inhibidores de la enzima lisosomal alfa-galactosidasa A, en donde dicho o más inhibidores se dispersan o disuelven en fase continua, en donde la fase continua es una fase acuosa, una fase orgánica o una fase oleosa; y uno o más excipientes farmacéuticamente aceptables opcionales, en donde los excipientes comprenden emolientes, espesantes, agentes tensioactivos ionicos o no ionicos y emulsionantes, agentes bacteriostáticos, agentes colorantes, esencias y gases propelentes, o combinaciones de los mismos. Reivindicacion 2: La composicion de acuerdo con la reivindicacion 1, caracterizada porque dicho o más inhibidores de la enzima lisosomal alfa-galactosidasa A comprenden sales 1-desoxigalactonojirimicina y derivados, iminoazucares y derivados, desoxi-aza-azucares y derivados, alcaloides calisteginas y derivados, isomeros de fagomina, conduritol C epoxidos, alcaloides nortropanos, o combinaciones de los mismos. Reivindicacion 4: La composicion de acuerdo con la reivindicacion 1, caracterizada porque el clorhidrato de 1-desoxigalactonojirimicina está presente en una cantidad que ascua entre alrededor del 1% y el 15% en peso en la composicion. Reivindicacion 5: La composicion de acuerdo con la reivindicacion 1, caracterizada porque la composicion se aplica al cuero cabelludo una vez al día o multiples veces al día. Reivindicacion 7: La composicion de acuerdo con la reivindicacion 1, caracterizada porque la formulacion farmacéutica topica es una solucion, una suspension, un ungüento, una espuma, una emulsion o una crema. Reivindicacion 20: Un método para tratar la calvicie o la alopecia en un sujeto, dicho método caracterizado porque comprende los pasos de: identificar un sujeto que necesita tratamiento contra la calvicie o la alopecia; y aplicar una formulacion farmacéutica topica que comprende uno o más inhibidores de la enzima lisosomal alfa-galactosidasa A al cuero cabelludo del sujeto una o multiples veces al día, en donde dicho o más inhibidores se dispersan o disuelven en fase continua, en donde la fase continua es una fase acuosa, una fase orgánica, o una fase oleosa.
ARP100103588A 2009-10-01 2010-10-01 Tratamiento de calvicie de patron masculino por induccion local del defecto metabolico de la enfermedad de fabry AR078498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24789409P 2009-10-01 2009-10-01

Publications (1)

Publication Number Publication Date
AR078498A1 true AR078498A1 (es) 2011-11-09

Family

ID=43826915

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103588A AR078498A1 (es) 2009-10-01 2010-10-01 Tratamiento de calvicie de patron masculino por induccion local del defecto metabolico de la enfermedad de fabry

Country Status (4)

Country Link
US (1) US20110112041A1 (es)
AR (1) AR078498A1 (es)
TW (1) TW201117810A (es)
WO (1) WO2011041718A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8876749B2 (en) 2006-11-27 2014-11-04 Frank Levy Apparatus and process for producing CO2 enriched medical foam
US9662435B2 (en) 2006-01-31 2017-05-30 Frank Levy System and method for the effective, reliable and foolproof delivery of controlled amounts of a medical fluid
US11185671B2 (en) 2006-11-27 2021-11-30 Frank Levy Apparatus and process for producing CO2 enriched medical foam
US9427522B2 (en) 2006-11-27 2016-08-30 Frank Levy Delivery system for the effective and reliable delivery of controlled amounts of a medical fluid
US11712510B2 (en) 2006-11-27 2023-08-01 Frank Levy Delivery system and method for the effective, reliable and foolproof delivery of controlled amounts of a medical fluid
US10149935B2 (en) 2006-11-27 2018-12-11 Frank Levy Delivery system and method for the effective and reliable delivery of controlled amounts of a medical fluid
US11833320B2 (en) 2006-11-27 2023-12-05 Frank Levy Apparatus and process for producing CO2 enriched medical foam
US10322271B2 (en) 2006-11-27 2019-06-18 Frank Levy Delivery system and method for the effective and reliable delivery of controlled amounts of a medical fluid
US10350399B2 (en) 2006-11-27 2019-07-16 Frank Levy Apparatus and method for producing an enriched medical suspension of carbon dioxide
US10155093B2 (en) 2006-11-27 2018-12-18 Frank Levy Apparatus and method for producing CO2 enriched medical foam
WO2015049549A1 (en) * 2013-10-01 2015-04-09 Beauty Thru Science Limited A method for stimulating scalp hair re-growth
US9949915B2 (en) 2016-06-10 2018-04-24 Clarity Cosmetics Inc. Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use
DE102016125344A1 (de) * 2016-12-22 2018-06-28 Peter Jürgensen Zubereitung zur Verwendung bei der Behandlung des erblich bedingten Haarausfalls
WO2020056191A1 (en) * 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
CN102586205A (zh) * 2003-01-31 2012-07-18 纽约大学西奈山医学院 酶和酶的活性部位特异性陪伴分子的组合
US20100113517A1 (en) * 2007-03-30 2010-05-06 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
AU2009214648B2 (en) * 2008-02-12 2014-11-13 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases

Also Published As

Publication number Publication date
US20110112041A1 (en) 2011-05-12
TW201117810A (en) 2011-06-01
WO2011041718A2 (en) 2011-04-07
WO2011041718A3 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
AR078498A1 (es) Tratamiento de calvicie de patron masculino por induccion local del defecto metabolico de la enfermedad de fabry
Randolph et al. Oral minoxidil treatment for hair loss: A review of efficacy and safety
Stough et al. Psychological effect, pathophysiology, and management of androgenetic alopecia in men
Sarkar et al. Chemical peels for melasma in dark-skinned patients
Vañó-Galván et al. New treatments for hair loss
Arif et al. Dutasteride in androgenetic alopecia: an update
JP5934781B2 (ja) 脱毛防止及び発毛促進用外用剤組成物
Fertig et al. Frontal fibrosing alopecia treatment options
ITMI20081401A1 (it) Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie
AU2017254952A1 (en) Compositions for skin exfoliation and use thereof
Guenther et al. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis
Devi et al. Intralesional triamcinolone acetonide versus topical betamethasone valearate in the management of localized alopecia areata
Guo et al. Experimental and early investigational drugs for androgenetic alopecia
CA2844142A1 (en) Method for enhancing the growth and fullness of hair
Gridelli et al. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting
Nusbaum et al. Nonsurgical therapy for hair loss
US9283163B2 (en) Collagen stimulators and their use in the treatment of skin
EP3129026A1 (en) Hair enhancing formulation
Tosti et al. Color atlas of chemical peels
Diernaes et al. Successful treatment of recalcitrant folliculitis barbae and pseudofolliculitis barbae with photodynamic therapy
AU2019342136A1 (en) Iron chelating compounds for treating aesthetic skin conditions
KR20160119690A (ko) 니코틴산 아데닌 디뉴클레오티드 인산 및 그 유도체를 포함하는 발모 또는 육모 촉진제
JP6996775B2 (ja) 個体の毛髪の成長を促進する、毛髪の抜けを予防する、または個体の毛包幹細胞の生成を促進する薬物の調製における組成物の用途
US20220395437A1 (en) Composition for the making of an emulsifiable triphasic formulation, and kit for the use of such composition
John et al. Emerging oral treatments: oral minoxidil for androgenetic alopecia

Legal Events

Date Code Title Description
FB Suspension of granting procedure